OrbiMed Advisors CRDF Position
ExitedOrbiMed Advisors exited their position in Cardiff Oncology, Inc. (CRDF) in Q2 2025, after holding the stock for 3 quarters.
The position was first reported in Q4 2024 and has been tracked across 3 quarterly 13F filings.
1 other tracked fund also holds CRDF.
Short interest stands at 26.1% of float with 23.3 days to cover, indicating significant bearish positioning against the stock.
About Cardiff Oncology, Inc.
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Full company profile →Short Interest
26.1%
23.3 days to cover
OrbiMed Advisors CRDF Position History
Frequently Asked Questions
Does OrbiMed Advisors own CRDF?
No. OrbiMed Advisors exited their position in Cardiff Oncology, Inc. (CRDF) in Q2 2025. They previously held the stock for 3 quarters.
How many hedge funds own CRDF?
1 specialist biotech hedge fund currently holds CRDF, including Commodore Capital. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy CRDF?
OrbiMed Advisors's position in CRDF was first reported in Q4 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's CRDF position increasing or decreasing?
OrbiMed Advisors completely exited their CRDF position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
CRDFCompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →